In the current studies, we show that the cytotoxic effect of BET inhibition in CTCL cells is synergistically potentiated by either BCL2 inhibition or HDAC inhibition in the vast majority of both patient-derived samples and CTCL cell lines. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.